These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 22210921

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [Abstract] [Full Text] [Related]

  • 3. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
    Okabe K, Beppu T, Haraoka K, Oh-Uchida Y, Yamamura S, Tomiyasu S, Yamanaka T, Sano O, Masuda T, Chikamoto A, Fujiyama S, Baba H.
    Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
    Okimoto K, Ogasawara S, Chiba T, Ooka Y, Oobu M, Azemoto R, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Yoshikawa M, Yokosuka O.
    Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma.
    Maeda S, Shibata J, Fujiyama S, Tanaka M, Noumaru S, Sato K, Tomita K.
    Hepatogastroenterology; 2003 Dec; 50(51):809-13. PubMed ID: 12828090
    [Abstract] [Full Text] [Related]

  • 6. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
    Oguro S, Hashimoto S, Tanaka T, Inoue M, Nakatsuka S, Kuribayashi S, Asakura K, Kawachi S, Tanabe M, Kitagawa Y, Ebinuma H, Saito H, Hibi T.
    Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
    [Abstract] [Full Text] [Related]

  • 7. Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
    Matsumoto T, Ichikawa H, Imai J, Hayashi T, Tomita K, Mine T, Kojima S, Watanabe N, Hasebe T.
    Anticancer Res; 2017 Jun; 37(6):3183-3187. PubMed ID: 28551662
    [Abstract] [Full Text] [Related]

  • 8. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
    Koizumi Y, Hirooka M, Uehara T, Kisaka Y, Uesugi K, Kumagi T, Abe M, Matsuura B, Hiasa Y, Onji M.
    Hepatogastroenterology; 2011 Jun; 58(106):512-5. PubMed ID: 21661422
    [Abstract] [Full Text] [Related]

  • 9. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.
    Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, Okusaka T, Japan Interventional Radiology in Oncology Study Group (JIVROSG), Korea Interventional Radiology in Oncology Study Group (KIVROSG).
    J Vasc Interv Radiol; 2013 Apr; 24(4):490-500. PubMed ID: 23466316
    [Abstract] [Full Text] [Related]

  • 10. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma.
    Kawaoka T, Aikata H, Katamura Y, Takaki S, Waki K, Hiramatsu A, Takahashi S, Hieda M, Kakizawa H, Chayama K.
    J Vasc Interv Radiol; 2010 Aug; 21(8):1219-25. PubMed ID: 20619676
    [Abstract] [Full Text] [Related]

  • 11. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
    Dohmen K, Shirahama M, Shigematsu H, Miyamoto Y, Torii Y, Irie K, Ishibashi H.
    Hepatogastroenterology; 2001 Aug; 48(41):1409-15. PubMed ID: 11677976
    [Abstract] [Full Text] [Related]

  • 12. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review.
    Idée JM, Guiu B.
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):530-49. PubMed ID: 23921081
    [Abstract] [Full Text] [Related]

  • 13. Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil.
    Ishida K, Hirooka M, Hiraoka A, Kumagi T, Uehara T, Hiasa Y, Horiike N, Onji M.
    Jpn J Clin Oncol; 2008 Sep; 38(9):596-603. PubMed ID: 18772170
    [Abstract] [Full Text] [Related]

  • 14. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
    Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hamaoka K, Fujimori K, Inao M, Nakayama N, Oka M, Nagoshi S, Mochida S.
    J Gastroenterol; 2012 Feb; 47(2):179-86. PubMed ID: 21976133
    [Abstract] [Full Text] [Related]

  • 15. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y, Liver Cancer Study Group of Japan.
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [Abstract] [Full Text] [Related]

  • 16. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
    Shirono T, Iwamoto H, Niizeki T, Shimose S, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Sakai M, Nomiyama M, Kuwano T, Tanaka M, Koga H, Torimura T.
    Oncology; 2019 Aug; 96(2):79-86. PubMed ID: 30293080
    [Abstract] [Full Text] [Related]

  • 17. [Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)--safety and efficacy in combination with embolizing agents].
    Ikeda K, Okusaka T, Ikeda M, Morimoto M.
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):271-5. PubMed ID: 20154484
    [Abstract] [Full Text] [Related]

  • 18. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
    Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T.
    Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma.
    Takaki S, Sakaguchi H, Anai H, Tanaka T, Yamamoto K, Morimoto K, Nishiofuku H, Inoue M, Sueyoshi S, Nagata T, Hidaka T, Uchida H, Kichikawa K.
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):544-54. PubMed ID: 21739345
    [Abstract] [Full Text] [Related]

  • 20. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B, Yu J, Wang L, Li C, Zhou T, Zhai L, Xing L.
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.